S&P 500   3,839.85
DOW   31,117.18
QQQ   322.82
S&P 500   3,839.85
DOW   31,117.18
QQQ   322.82
S&P 500   3,839.85
DOW   31,117.18
QQQ   322.82
S&P 500   3,839.85
DOW   31,117.18
QQQ   322.82
Log in

Akero Therapeutics Stock Forecast, Price & News

+0.74 (+2.50 %)
(As of 01/20/2021 11:22 AM ET)
Today's Range
Now: $30.33
50-Day Range
MA: $27.33
52-Week Range
Now: $30.33
Volume3,844 shs
Average Volume466,788 shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.


Overall MarketRank

1.49 out of 5 stars

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AKRO



Sales & Book Value

Annual SalesN/A
Book Value$4.51 per share


Net Income$-43,760,000.00


Market Cap$1.05 billion
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable
+0.74 (+2.50 %)
(As of 01/20/2021 11:22 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Akero Therapeutics (NASDAQ:AKRO) Frequently Asked Questions

How has Akero Therapeutics' stock been impacted by Coronavirus?

Akero Therapeutics' stock was trading at $21.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AKRO shares have increased by 43.2% and is now trading at $30.08.
View which stocks have been most impacted by COVID-19

Is Akero Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Akero Therapeutics stock.
View analyst ratings for Akero Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Akero Therapeutics?

Wall Street analysts have given Akero Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Akero Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Akero Therapeutics' next earnings date?

Akero Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Akero Therapeutics

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) released its quarterly earnings results on Tuesday, November, 17th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.04.
View Akero Therapeutics' earnings history

What price target have analysts set for AKRO?

6 analysts have issued twelve-month price targets for Akero Therapeutics' stock. Their forecasts range from $41.00 to $79.00. On average, they anticipate Akero Therapeutics' stock price to reach $58.83 in the next year. This suggests a possible upside of 95.6% from the stock's current price.
View analysts' price targets for Akero Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Akero Therapeutics' key competitors?

What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), (NGM) and VIVUS (VVUS).

Who are Akero Therapeutics' key executives?

Akero Therapeutics' management team includes the following people:
  • Dr. Andrew Cheng, Pres, CEO & Director (Age 53, Pay $747.05k)
  • Dr. Jonathan M. Young, Co-Founder, EVP & COO (Age 50, Pay $600k)
  • Mr. Timothy Rolph, Co-Founder & Chief Scientific Officer (Age 66, Pay $600k)
  • Mr. William R. White J.D., Exec. VP, CFO & Head of Corp. Devel. (Age 47, Pay $494.3k)
  • Ms. Kitty Yale, Exec. VP & Chief Devel. Officer (Age 48)
  • Mr. John J. Schembri, VP of Fin. & Controller (Age 58)

When did Akero Therapeutics IPO?

(AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is Akero Therapeutics' stock symbol?

Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO."

How do I buy shares of Akero Therapeutics?

Shares of AKRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akero Therapeutics' stock price today?

One share of AKRO stock can currently be purchased for approximately $30.08.

How big of a company is Akero Therapeutics?

Akero Therapeutics has a market capitalization of $1.04 billion. The company earns $-43,760,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Akero Therapeutics employs 16 workers across the globe.

What is Akero Therapeutics' official website?

The official website for Akero Therapeutics is www.akerotx.com.

How can I contact Akero Therapeutics?

Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-487-6488 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.